Toll-like receptor signaling directly increases functional IL-17RA expression in neuroglial cells

Clinical Immunology

Volumn 154, Issue 2, 2014, Pages 127-140

  Liu, Guoping ^a   Guo, Jie ^a   Liu, Jin ^a   Wang, Zhiyun ^a   Liang, Dongchun ^b  

^a TIANJIN FIRST CENTRAL HOSPITAL   (China)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Astrocytes; Expression; IL 17RA; Toll like receptor

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17 RECEPTOR A; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GLIA CELL; IMMUNIZATION; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MICROGLIA; MOUSE; NONHUMAN; OLIGODENDROGLIA; SIGNAL TRANSDUCTION; SPINAL CORD;

ASTROCYTES; EXPRESSION; IL-17RA; TOLL-LIKE RECEPTOR;

ANIMALS; CHEMOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; INTERLEUKIN-17; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROGLIA; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84905667955     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.07.006     Document Type: Article

References (52)

1. Peterson L.K., Fujinami R.S. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J. Neuroimmunol. Mar 2007, 184(1-2):37-44.
2. Krakowski M.L., Owens T. Naive T lymphocytes traffic to inflamed central nervous system, but require antigen recognition for activation. Eur. J. Immunol. Apr 2000, 30(4):1002-1009.
3. Nair A., Frederick T.J., Miller S.D. Astrocytes in multiple sclerosis: a product of their environment. Cell. Mol. Life Sci. Sep 2008, 65(17):2702-2720.
4. Dong Y., Benveniste E.N. Immune function of astrocytes. Glia Nov 2001, 36(2):180-190.
5. Calderon T.M., Eugenin E.A., Lopez L., Kumar S.S., Hesselgesser J., Raine C.S., et al. A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J. Neuroimmunol. Aug 2006, 177(1-2):27-39.
6. Yang J.F., Tao H.Q., Liu Y.M., Zhan X.X., Liu Y., Wang X.Y., et al. Characterization of the interaction between astrocytes and encephalitogenic lymphocytes during the development of experimental autoimmune encephalitomyelitis (EAE) in mice. Clin. Exp. Immunol. Dec 2012, 170(3):254-265.
7. Meares G.P., Ma X., Qin H., Benveniste E.N. Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. Glia May 2012, 60(5):771-781.
8. Lovett-Racke A.E., Yang Y., Racke M.K. Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis?. Biochim. Biophys. Acta Feb 2011, 1812(2):246-251.
9. Aggarwal S., Ghilardi N., Xie M.H., de Sauvage F.J., Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. Jan 17 2003, 278(3):1910-1914.
10. Chang S.H., Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell. Signal. Jul 2011, 23(7):1069-1075.
11. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. Jul 1 2006, 177(1):566-573.
12. Das S.J., Ciric B., Marek R., Sadhukhan S., Caruso M.L., Shafagh J., et al. Functional interleukin-17 receptor A is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitis. J. Neuroinflammation 2009, 6:14.
13. Kang Z., Altuntas C.Z., Gulen M.F., Liu C., Giltiay N., Qin H., et al. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity Mar 26 2010, 32(3):414-425.
14. Yan Y., Ding X., Li K., Ciric B., Wu S., Xu H., et al. CNS-specific therapy for ongoing EAE by silencing IL-17 pathway in astrocytes. Mol. Ther. Jul 2012, 20(7):1338-1348.
15. Kang Z., Liu L., Spangler R., Spear C., Wang C., Gulen M.F., et al. IL-17-induced Act1-mediated signaling is critical for cuprizone-induced demyelination. J. Neurosci. Jun 13 2012, 32(24):8284-8292.
16. Gelderblom M., Weymar A., Bernreuther C., Velden J., Arunachalam P., Steinbach K., et al. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood Nov 1 2012, 120(18):3793-3802.
17. Pradhan V.D., Das S., Surve P., Ghosh K. Toll-like receptors in autoimmunity with special reference to systemic lupus erythematosus. Indian J. Hum. Genet. May 2012, 18(2):155-160.
18. Theofilopoulos A.N. TLRs and IFNs: critical pieces of the autoimmunity puzzle. J. Clin. Invest. Oct 1 2012, 122(10):3464-3466.
19. Horton C.G., Farris A.D. Toll-like receptors in systemic lupus erythematosus: potential targets for therapeutic intervention. Curr. Allergy Asthma Rep. Feb 2012, 12(1):1-7.
20. Hoffmann M.H., Skriner K., Herman S., Baumann C., Steiner C.W., Ospelt C., et al. Nucleic acid-stimulated antigen-presenting cells trigger T cells to induce disease in a rat transfer model of inflammatory arthritis. J. Autoimmun. May 2011, 36(3-4):288-300.
21. Nichols J.R., Aldrich A.L., Mariani M.M., Vidlak D., Esen N., Kielian T. TLR2 deficiency leads to increased Th17 infiltrates in experimental brain abscesses. J. Immunol. Jun 1 2009, 182(11):7119-7130.
22. Aguirre A., Maturana C.J., Harcha P.A., Saez J.C. Possible involvement of TLRs and hemichannels in stress-induced CNS dysfunction via mastocytes, and glia activation. Mediat. Inflamm. 2013, 2013:893521.
23. Imaizumi T., Murakami K., Ohta K., Seki H., Matsumiya T., Meng P., et al. MDA5 and ISG56 mediate CXCL10 expression induced by toll-like receptor 4 activation in U373MG human astrocytoma cells. Neurosci. Res. Aug 2013, 76(4):195-206.
24. Vontell R., Supramaniam V., Thornton C., Wyatt-Ashmead J., Mallard C., Gressens P., et al. Toll-like receptor 3 expression in glia and neurons alters in response to white matter injury in preterm infants. Dev. Neurosci. 2013, 35(2-3):130-139.
25. Brandenburg L.O., Jansen S., Albrecht L.J., Merres J., Gerber J., Pufe T., et al. CpG oligodeoxynucleotides induce the expression of the antimicrobial peptide cathelicidin in glial cells. J. Neuroimmunol. Feb 15 2013, 255(1-2):18-31.
26. Jiang G., Sun D., Kaplan H.J., Shao H. Retinal astrocytes pretreated with NOD2 and TLR2 ligands activate uveitogenic T cells. PLoS One 2012, 7(7):e40510.
27. Chen S., Yan H., Sun B., Zuo A., Liang D. Subretinal transfection of chitosan-loaded TLR3-siRNA for the treatment of experimental autoimmune uveitis. Eur. J. Pharm. Biopharm. Nov 17 2013, 85(3 Pt A):726-735.
28. Wang Y., Zhu W., Levy D.E. Nuclear and cytoplasmic mRNA quantification by SYBR green based real-time RT-PCR. Methods Aug 2006, 39(4):356-362.
29. Kolls J.K., Linden A. Interleukin-17 family members and inflammation. Immunity Oct 2004, 21(4):467-476.
30. Ishigame H., Kakuta S., Nagai T., Kadoki M., Nambu A., Komiyama Y., et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity Jan 16 2009, 30(1):108-119.
31. Sarkar S., Justa S., Brucks M., Endres J., Fox D.A., Zhou X., et al. IL-17A, F, and AF in inflammation: a study in collagen induced arthritis and rheumatoid arthritis. Clin. Exp. Immunol. Sep 12 2014, 177(3):652-661.
32. Hot A., Miossec P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann. Rheum. Dis. May 2011, 70(5):727-732.
33. Hot A., Zrioual S., Toh M.L., Lenief V., Miossec P. IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. Ann. Rheum. Dis. Feb 2011, 70(2):341-348.
34. Chen Y., Yang P., Li F., Kijlstra A. The effects of Th17 cytokines on the inflammatory mediator production and barrier function of ARPE-19 cells. PLoS One 2011, 6(3):e18139.
35. Hu Y., Ota N., Peng I., Refino C.J., Danilenko D.M., Caplazi P., et al. IL-17RC is required for IL-17A- and IL-17F-dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. Apr 15 2010, 184(8):4307-4316.
36. Ho A.W., Gaffen S.L. IL-17RC: a partner in IL-17 signaling and beyond. Semin. Immunopathol. Mar 2010, 32(1):33-42.
37. Toy D., Kugler D., Wolfson M., Vanden B.T., Gurgel J., Derry J., et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J. Immunol. Jul 1 2006, 177(1):36-39.
38. Toy D., Kugler D., Wolfson M., Vanden B.T., Gurgel J., Derry J., et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J. Immunol. Jul 1 2006, 177(1):36-39.
39. Ho A.W., Shen F., Conti H.R., Patel N., Childs E.E., Peterson A.C., et al. IL-17RC is required for immune signaling via an extended SEF/IL-17R signaling domain in the cytoplasmic tail. J. Immunol. Jul 15 2010, 185(2):1063-1070.
40. Ho A.W., Gaffen S.L. IL-17RC: a partner in IL-17 signaling and beyond. Semin. Immunopathol. Mar 2010, 32(1):33-42.
41. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. Aug 2009, 9(8):556-567.
42. Yao Z., Fanslow W.C., Seldin M.F., Rousseau A.M., Painter S.L., Comeau M.R., et al. Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. J. Immunol. Nov 1 2011, 187(9):4392-4402.
43. Lindemann M.J., Hu Z., Benczik M., Liu K.D., Gaffen S.L. Differential regulation of the IL-17 receptor by gammac cytokines: inhibitory signaling by the phosphatidylinositol 3-kinase pathway. J. Biol. Chem. May 16 2008, 283(20):14100-14108.
44. O'Connor W., Kamanaka M., Booth C.J., Town T., Nakae S., Iwakura Y., et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. Jun 2009, 10(6):603-609.
45. Fellner L., Irschick R., Schanda K., Reindl M., Klimaschewski L., Poewe W., et al. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia Mar 2013, 61(3):349-360.
46. Saito O., Svensson C.I., Buczynski M.W., Wegner K., Hua X.Y., Codeluppi S., et al. Spinal glial TLR4-mediated nociception and production of prostaglandin E(2) and TNF. Br. J. Pharmacol. Aug 2010, 160(7):1754-1764.
47. Park C., Cho I.H., Kim D., Jo E.K., Choi S.Y., Oh S.B., et al. Toll-like receptor 2 contributes to glial cell activation and heme oxygenase-1 expression in traumatic brain injury. Neurosci. Lett. Jan 31 2008, 431(2):123-128.
48. Jou I., Lee J.H., Park S.Y., Yoon H.J., Joe E.H., Park E.J. Gangliosides trigger inflammatory responses via TLR4 in brain glia. Am. J. Pathol. May 2006, 168(5):1619-1630.
49. Zhu W., Meng L., Jiang C., He X., Hou W., Xu P., et al. Arthritis is associated with T-cell-induced upregulation of Toll-like receptor 3 on synovial fibroblasts. Arthritis Res. Ther. 2011, 13(3):R103.
50. Lee S.Y., Yoon B.Y., Kim J.I., Heo Y.M., Woo Y.J., Park S.H., et al. Interleukin-17 increases the expression of Toll-like receptor 3 via the STAT3 pathway in rheumatoid arthritis fibroblast-like synoviocytes. Immunology Mar 2014, 141(3):353-361.
51. Graeler M., Goetzl E.J. Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J. Dec 2002, 16(14):1874-1878.
52. Damsker J.M., Bukrinsky M.I., Constant S.L. Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin A. J. Leukoc. Biol. Sep 2007, 82(3):613-618.